美股A股
StockGist
Back
10-Q2026-05-15· grok-4-1-fast-non-reasoning

INDP · Indaptus Therapeutics, Inc.

0001493152-26-023362

SEC filing

Summary

Indaptus Therapeutics narrowed its Q1 FY2026 operating loss by 52.8% to -$2.2M and net loss by 43.9% to -$2.5M versus prior year, driven by lower expenses following clinical trial discontinuation and management transition, though cash burn accelerated due to liability paydowns.

Key takeaways

Full analysis

Indaptus Therapeutics, Inc. reported meaningful improvement in its Q1 FY2026 operating results compared to the prior year, with operating income narrowing 52.8% to -$2.2 million from -$4.6 million. This progress stems from the discontinuation and winding down of the Combination Study, which management indicates will lead to decreased research and development expenses in the short term. The smaller operating loss reflects disciplined cost management in a pre-revenue clinical-stage biotechnology context, where the company has no approved products and has never generated revenue from product sales.

Net income followed a similar trajectory, improving 43.9% to -$2.5 million from -$4.5 million year-over-year, with diluted EPS advancing 28.1% to -$0.23 from -$0.32. These enhancements underscore the impact of lower expenses across key areas. Notably, general and administrative expenses benefited from a decrease attributable to reduced costs related to operating as a public company, tied to the transition of management. Management expects these G&A expenses to continue decreasing in the short term following the Combination Study wind-down, though potential offsets could arise from costs related to any Post Investment Transaction.